Bicara Therapeutics Inc BCAX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $17.26
- Day Range
- $17.11–17.60
- 52-Week Range
- $13.79–30.92
- Bid/Ask
- $17.53 / $17.66
- Shares Outstanding
- 66.17M
- Market Cap
- $1.16B
- Volume/Avg
- 124,194 / 624,104
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 103
- Website
- https://www.bicara.com
Valuation
|
Metric
|
BCAX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.43 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
BCAX
Financial Strength
|
Metric
|
BCAX
|
|---|---|
Quick Ratio | 11.44 |
Current Ratio | 11.59 |
Interest Coverage | — |
Quick Ratio
BCAX
Profitability
|
Metric
|
BCAX
|
|---|---|
Return on Assets (Normalized) | −35.34% |
Return on Equity (Normalized) | −37.77% |
Return on Invested Capital (Normalized) | −40.61% |
Return on Assets
BCAX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|DMdDRBQ | LOCK|KNQ& | $128B | |||
| Moderna Inc
MRNA
| LOCK|#S?Q<g | LOCK|Xv | $79B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|%<%tsVD | LOCK|d!D$> | $76B | |||
| argenx SE ADR
ARGX
| LOCK|!SjKZ> | LOCK|>Mv | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|&y$%B% | LOCK|<>% | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|@sZc%&% | LOCK|QD%? | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|GdXYB$!P | LOCK|FRp^V | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|X>^vLd | LOCK|%$ | $23B | |||
| Incyte Corp
INCY
| LOCK|VyHCL? | LOCK|#d | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|GPrq$>^ | LOCK|V$ | $14B |
United States